Test Bank For Karch's Focus On Nursing Pharmacology, 9Th Edition By Rebecca Tucker/All Chapters 1-59/Complete Guide

Stuvia.com bb- bbThe bbMarketplace bbto bbBuy bband bbSell bbyour
bbStudy bbMaterial

Test bbBank bb- bbFocus bbon bbNursing bbPharmacology bb(9th bbEdition bbby bbKarch) 3


TEST BANK FOR KARCH'S FOCUS ON NURSING
bb bb bb bb bb bb



PHARMACOLOGY, 9TH EDITION BY REBECCA
bb bb bb bb bb



TUCKER/ALLCHAPTERS 1-59/COMPLETE GUIDE 2026-2027
bb b bb bb bb

, Stuvia.com bb- bbThe bbMarketplace bbto bbBuy bband bbSell bbyour
bbStudy bbMaterial

Test bbBank bb- bbFocus bbon bbNursing bbPharmacology bb(9th bbEdition bbby bbKarch) 3


Chapter 01 - Introduction to drugs
bb bb bb bb bb bb




A bbmedical bbattendant bbworking bbin bbradiology bbadministers bbiodine bbto bba bbhospital bbclient bbwho bbis
bbhaving bba bbcomputed bbtomography bb(CT)scan. bbThe bbmedical bbattendant bbworking bbon bbthe

bboncology bbunit bbadministers bbchemotherapy bbto bbhospital bbclients bbwhobhave bbcancer. bbAt bbthe

bbPublic bbHealth bbDepartment, bba bbmedical bbattendant bbadministers bba bbmeasles-mumps-

rubellab(MMR) bbvaccine bbto bba bb14-month-old bbchild bbas bba bbroutine bbimmunization. bbWhich
bbbranch bbof bbpharmacology bbbest bbdescribes bbthe bbactions bbof bball bbthree bbmedical bbattendants?




Pharmacoeconomics


bbPharmacotherapeuti


csbPharmacodynamics


bbPharmacokinetics


bbACCURATE


bbANS:- bbB


Reasoning:->>>


Pharmacology bbis bbthe bbstudy bbof bbthe bbbiologic bbeffects bbof bbchemicals. bbMedical bbattendants bbare
bbinvolved bbwith bbclinical bbpharmacology bbor bbpharmacotherapeutics, bbwhich bbis bba bbbranch bbof

bbpharmacology bbthat bbdeals bbwith bbthe bbuses bbofbbbdrugs bbto bbtreat, bbprevent, bband bbdiagnose bbsickness.

bbThe bbradiology bbmedical bbattendant bbis bbadministering bba bb bbdrug bbto bbhelp bbdiagnose bba bbsickness. bbThe

bboncology bbmedical bbattendant bbis bbadministering bba bb bbdrug bbto bbhelp bbtreat bba bbsickness.

Pharmacoeconomics bbincludes bbany bbcosts bbinvolved bbin bb bbdrug bbtherapy. bbPharmacodynamics
bbinvolvesbhow bba bb bbdrug bbaffects bbthe bbbody bband bbpharmacokinetics bbis bbhow bbthe bbbody bbacts bbon bbthe
bbbody.




A bbphysician bbhas bbordered bbintramuscular bb(IM) bbinjections bbof bbmorphine, bba bbnarcotic, bbevery bb4 bbhours bbas
bbneeded bbforbpain bbin bba bbmotor bbvehicle bbaccident bbvictim. bbThe bbmedical bbattendant bbis bbaware bbthis bb
bbdrug bbhas bba bbhigh bbabuse bbpotential.

Under bbwhat bbcategory bbwould bbmorphine bbbe bbclassified?


Schedule bbI


bbSchedule


bbII


bbSchedule


bbIIIbSchedul

, Stuvia.com bb- bbThe bbMarketplace bbto bbBuy bband bbSell bbyour
bbStudy bbMaterial

Test bbBank bb- bbFocus bbon bbNursing bbPharmacology bb(9th bbEdition bbby bbKarch) 3
e


bb IVbCORRE


CT


CHOICE:- bbB
Reasoning:->>>


Narcotics bbwith bba bbhigh bbabuse bbpotential bbare bbclassified bbas bbSchedule bbII bb bbdrugs bbbecause bbof bbsevere

dependencebliability. b b Schedule b b I b b bbdrugs b b have b b high b b abuse b b potential b b and b b no bb accepted b b medical
bb




bb use. b b Schedule
III b b bbdrugs bbhave b b a b b lesser b b abuse b b potential b b than b b II b b and b b an b b accepted b b medical
b b use. b b Schedule b b IVbbbdrugs bbhave bblow bbabusepotential bband bblimited bbdependence bbliability.




When bbinvolved bbin bbphase bbIII bb bbdrug bbevaluation bbstudies, bbwhat bbresponsibilities bbwould


thebmedical bbattendant bbhave?Working bbwith bbanimals bbwho bbare bbgiven bbexperimental bb bbdrugs
bb




Choosing bbappropriate bbhospital bbclients bbto bbbe bbinvolved bbin bbthe bb


bb drug bbstudybMonitoring bband bbobserving bbhospital bbclients bbclosely


bb for bbadverse bbeffects bbConducting bbresearch bbto bbdetermine


bb effectiveness bbof bbthe bb bbdrug bbACCURATE bbANS:- b b C


Reasoning:->>>


Phase bbIII bbstudies bbinvolve bbuse bbof bba bb bbdrug bbin bba bbvast bbclinical bbpopulation bbin bbwhich bbhospital
bbclients bbare bbasked bbto bbrecordany bbsymptoms bbthey bbexperience bbwhile bbtaking bbthe bb bbdrugs. bbMedical

bbattendants bbmay bbbe bbresponsible bbfor bbhelping bbcollect bband bbanalyze bbthe bbinformation bbto bbbe bbshared

bbwith bbthe bbFood bband bb bbdrug bbAdministration bb(FDA) bbbut bbwould bbnot bbconduct bbresearch

bbindependently bbbecause bbmedical bbattendants bbdo bbnot bbprescribe bb bbdrugs.bUse bbof bbanimals bbin bb bbdrug

bbtesting bbis bbdone bbin bbthe bbpreclinical bbtrials. bbSelect bbhospital bbclients bbwho bbare bbinvolved bbin bbphase

bbII bbstudies bbto bbparticipatein bbstudies bbwhere bbthe bbparticipants bbhave bbthe bbsickness bbthe bb bbdrug bbis

bbintended bbto bbtreat. bbThese bbhospital bbclients bbare bbmonitored bbclosely bbfor bb bbdrug bbaction bband bbadverse

bbeffects. bbPhase bbIb studies bbinvolve bbhealthy bbhuman bbvolunteers bbwho bbare bbusually bbpaid bbfor bbtheir
bbparticipation. bbMedical bbattendants bbmay bbobserve bbfor bbadverse bbeffects bband bbtoxicity.




What bbconcept bbis bbconsidered bbwhen bbgeneric bb bbdrugs bbare bbsubstituted bbfor bbbrand bbnameb


bb drugs?Bioavailability


Critical


bb concentrationbDistrib

, Stuvia.com bb- bbThe bbMarketplace bbto bbBuy bband bbSell bbyour
bbStudy bbMaterial

Test bbBank bb- bbFocus bbon bbNursing bbPharmacology bb(9th bbEdition bbby bbKarch) 3
ution


Half-life


bbACCURAT


E bbANS:- bbA


Reasoning:->>>